Effect of Research Impact on Emerging Camel Husbandry, Welfare and Social-Related Awareness

The lack of applied scientific research on camels, despite them being recognized as production animals, compels the reorganization of emerging camel breeding systems with the aim of achieving successful camel welfare management strategies all over the world. Relevant and properly-framed research widely impacts dissemination of scientific contents and drives public willingness to enhance ethically acceptable conditions for domestic animals. Consumer perception of this livestock industry will improve and high-quality products will be obtained. This paper draws on bibliometric indicators as promoting factors for camel-related research advances, tracing historical scientific publications indexed in ScienceDirect directory from 1880–2019. Camel as a species did not affect Journal Citation Reports (JCR) impact (p > 0.05) despite the journal, author number, corresponding author origin, discipline and publication year affecting it (p < 0.001). Countries with traditionally well-established camel farming are also responsible for the papers with the highest academic impact. However, camel research advances may have only locally and partially influenced welfare related laws, so intentional harming acts and basic needs neglect may persist in these species. A sustainable camel industry requires those involved in camel research to influence business stakeholders and animal welfare advocacies by highlighting the benefits of camel wellbeing promotion, co-innovation partnership establishment and urgent enhancement of policy reform

Comportamento das doenças respiratórias no serviço de urgência do hospital pediátrico de Cienfuegos

Introduction: are largely responsible for the morbidity treated in pediatric institutions. Objective: to characterize the respiratory diseases behavior in the emergency department at the Hospital Pediátrico Universitario “Paquito González Cueto”, Cienfuegos, in 2020. Method: an observational, descriptive, and cross-sectional study was conducted in the Emergency Department at the Pediatric Hospital in Cienfuegos, from January through December, 2020. Population studied were children 0 to 18 years of age from Cienfuegos province who attended at the emergency department during the study period. The main variables assessed were the age groups and demand for medical consultations. All the statistical methods and techniques applied were those in the descriptive statistics. Results: the highest incidence of acute respiratory infections was reported in the months of march and February (758 and 668 consultations respectively), coinciding in the same period the bronchial asthma crises (101 and 111 consultations respectively). Pneumonias showed the highest morbidity in march (31.6 % of the cases). The predominant age group was 1 to 4 years. Conclusions: the respiratory diseases behavior was within the expected parameters, leading in incidence and morbidity the age group1 to 4 years and the first quarter of the year was the highest period on medical consultations medical consultations related to diseases studied.Introducción: las enfermedades respiratorias son responsables, en gran medida, de la morbilidad atendida en las instituciones pediátricas.Objetivo: caracterizar el comportamiento de las afecciones respiratorias en el servicio de Urgencias del Hospital Pediátrico Universitario “Paquito González Cueto”, de Cienfuegos, durante el año 2020. Método: se realizó un estudio observacional, descriptivo de corte transversal en el Servicio de Urgencias del Hospital Pediátrico de Cienfuegos del 1 de enero al 31 de diciembre de 2020. La población estudiada fueron los habitantes de edad pediátrica comprendida de 0 a 18 años de la provincia de Cienfuegos que asistieron al escenario y periodo de estudio. Las principales variables de estudio consideradas fueron los grupos de edades y demanda de consultas médicas. Los métodos y técnicas estadísticas utilizadas fueron de la estadística descriptiva. Resultados: la mayor incidencia de las infecciones respiratorias agudas fue en el mes de marzo y febrero con un total de 758 y 668 consultas respectivamente, coincidiendo este período para las crisis de asma bronquial con 101 y 111 consultas en iguales meses. Las neumonías mostraron mayor morbilidad en marzo con el 31,6 % de los casos. El predominio según grupo de edad se encontró de 1-4 años en las enfermedades estudiadas. Conclusiones: el comportamiento de las enfermedades respiratorias se encontró dentro de los parámetros esperados, siendo el grupo etario de mayor incidencia y morbilidad el de 1-4 años de edad, con predominio del número de consultas en el primer trimestre del año.Introdução: as doenças respiratórias são responsáveis, em grande parte, pela morbidade observada nas instituições pediátricas. Objetivo: caracterizar o comportamento das doenças respiratórias no Serviço de Emergência do Hospital Pediátrico Universitario “Paquito González Cueto”, em Cienfuegos, durante o ano de 2020. Método: foi realizado um estudo observacional, descritivo, transversal, no Serviço de Urgência do Hospital Pediátrico de Cienfuegos de 1 de janeiro a 31 de dezembro de 2020. A população estudada foi constituída por habitantes em idade pediátrica de 0 a 18 anos da província de Cienfuegos que frequentou o estágio e período de estudos. As principais variáveis consideradas no estudo foram a faixa etária e a demanda por consultas médicas. Os métodos e técnicas estatísticas utilizadas foram estatísticas descritivas. Resultados: a maior incidência de infecções respiratórias agudas foi em março e fevereiro com um total de 758 e 668 consultas, respectivamente, período esse coincidindo para as crises de asma brônquica com 101 e 111 consultas nos mesmos meses. A pneumonia apresentou maior morbidade em março com 31,6% dos casos. A predominância de acordo com a faixa etária foi encontrada entre 1 a 4 anos nas doenças estudadas. Conclusões: o comportamento das doenças respiratórias ficou dentro dos parâmetros esperados, sendo a faixa etária de maior incidência e morbidade a de 1 a 4 anos, com predomínio do número de consultas no primeiro trimestre do ano

Behavior of respiratory diseases in the emergency service of the pediatric hospital of Cienfuegos

Introduction: are largely responsible for the morbidity treated in pediatric institutions. Objective: to characterize the respiratory diseases behavior in the emergency department at the Hospital Pediátrico Universitario “Paquito González Cueto”, Cienfuegos, in 2020. Method: an observational, descriptive, and cross-sectional study was conducted in the Emergency Department at the Pediatric Hospital in Cienfuegos, from January through December, 2020. Population studied were children 0 to 18 years of age from Cienfuegos province who attended at the emergency department during the study period. The main variables assessed were the age groups and demand for medical consultations. All the statistical methods and techniques applied were those in the descriptive statistics. Results: the highest incidence of acute respiratory infections was reported in the months of march and February (758 and 668 consultations respectively), coinciding in the same period the bronchial asthma crises (101 and 111 consultations respectively). Pneumonias showed the highest morbidity in march (31.6 % of the cases). The predominant age group was 1 to 4 years. Conclusions: the respiratory diseases behavior was within the expected parameters, leading in incidence and morbidity the age group1 to 4 years and the first quarter of the year was the highest period on medical consultations medical consultations related to diseases studied

Obstructive Sleep Apnoea Syndrome, Endothelial Function and Markers of Endothelialization. Changes after CPAP

Study objectives This study tries to assess the endothelial function in vivo using flow-mediated dilatation (FMD) and several biomarkers of endothelium formation/restoration and damage in patients with obstructive sleep apnoea (OSA) syndrome at baseline and after three months with CPAP therapy. Design Observational study, before and after CPAP therapy. Setting and Patients We studied 30 patients with apnoea/hypopnoea index (AHI) > 15/h that were compared with themselves after three months of CPAP therapy. FMD was assessed non-invasively in vivo using the Laser-Doppler flowmetry. Circulating cell-free DNA (cf-DNA) and microparticles (MPs) were measured as markers of endothelial damage and the vascular endothelial growth factor (VEGF) was determined as a marker of endothelial restoration process. Measurements and results After three month with CPAP, FMD significantly increased (1072.26 +/- 483.21 vs. 1604.38 +/- 915.69 PU, p<0.005) cf-DNA and MPs significantly decreased (187.93 +/- 115.81 vs. 121.28 +/- 78.98 pg/ml, p<0.01, and 69.60 +/- 62.60 vs. 39.82 +/- 22.14 U/mu L, p<0.05, respectively) and VEGF levels increased (585.02 +/- 246.06 vs. 641.11 +/- 212.69 pg/ml, p<0.05). These changes were higher in patients with more severe disease. There was a relationship between markers of damage (r = -0.53, p< 0.005) but not between markers of damage and restoration, thus suggesting that both types of markers should be measured together. Conclusions CPAP therapy improves FMD. This improvement may be related to an increase of endothelial restoration process and a decrease of endothelial damage

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

Background: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. Methods: This phase II trial evaluated the efficacy and safety of response‐adapted therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD) in follicular lymphoma patients who relapsed after or were refractory to first‐line immunochemotherapy. Sixty patients received three treatment cycles, and depending on their response received an additional one (complete/unconfirmed complete response) or three (partial response) cycles. Patients who responded to induction received rituximab maintenance therapy for 2 years. Results: Thirty‐three (55%) and 42 (70%) patients achieved complete/unconfirmed complete response after three cycles and on completing induction therapy (4‐6 cycles), respectively (final overall response rate, 88.3%). Median progression‐free survival was 56.4 months (median follow‐up, 28.3 months; 95% CI, 15.6‐51.2). Overall survival was not reached. Progression‐free survival did not differ between patients who received four vs six cycles (P = .6665), nor between patients who did/did not receive rituximab maintenance after first‐line therapy (P = .5790). Median progression‐ free survival in the 10 refractory patients was 25.5 months (95% CI, 0.6‐N/A) and was longer in patients who had shown progression of disease after 24 months of first‐line therapy (median, 56.4 months; 95% CI, 19.8‐56.4) than in those who showed early progression (median, 42.31 months; 95% CI, 24.41–NA) (P = .4258). Thirty‐six (60%) patients had grade 3/4 neutropenia. Grade 3/4 febrile neutropenia and infection were recorded during induction (4/60 [6.7%] and 5/60 [8.3%] patients, respectively) and maintenance (2/43 [4.5%] and 4/43 [9.1%] patients, respectively). Conclusions: This response‐adapted treatment with RBMD followed by rituximab maintenance is an effective and well‐tolerated salvage treatment for relapsed/refractory follicular lymphoma following first‐line immunochemotherapy. Clinical trial registration: ClinicalTrials.gov # NCT01133158

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

Background and Objectives The elective treatment of patients with post-transplant lymphoproliferative disorders is controversial. The purpose of this trial was to evaluate the efficacy of treatment with extended doses of rituximab adapted to the response in patients with post-transplant lymphoproliferative disorders after solid organ transplantation. Design and Methods This was a prospective, multicenter, phase 11 trial. Patients were treated with reduction of immunosuppression and four weekly infusions of rituximab. Those patients who did not achieve complete remission (CR) received a second course of four rituximab infusions. The primary end-point of the study was the CR rate. Results Thirty-eight patients were assesable. One episode of grade 4 neutropenia was the only severe adverse event observed. After the first course of rituximab, 13 (34.2%) patients achieved CR, 8 patients did not respond, and 17 patients achieved partial remission. Among those 17 patients, 12 could be treated with a second course of rituximab, and 10 (83.3%) achieved CR, yielding an intention-to-treat CR rate of 60.5%. Eight patients excluded from the trial because of absence of CR were treated with rituximab combined with chemotherapy, and six (75%) achieved CR. Event-free survival was 42% and overall survival was 47% at 27.5 months. Fourteen patients died, ten of progression of their post-transplant lymphoproliferative disorder. Interpretation and Conclusions These results confirm that extended treatment with rituximab can obtain a high rate of CR in patients with post-transplant lymphoproliferative disorders after solid organ transplantation without increasing toxicity, and should be recommended as initial therapy for these patients

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

Innovación en las enseñanzas universitarias: experiencias presentadas en las III Jornadas de Innovación Educativa de la ULL

En este libro se recoge un conjunto de experiencias de innovación educativa desarrolladas en la ULL en el curso 2011-12. Se abordan distintos ámbitos y ramas del conocimiento, y ocupan temáticas variadas que han sido desarrolladas con rigor, y con un claro potencial para su extrapolación a efectos de la mejora educativa en el ámbito universitario. Esta publicación constituye una primera edición de una serie que irá recogiendo las experiencias de innovación educativa de la ULL. Este es un paso relevante para su impulso en nuestra institución, como lo es el de su vinculación con la investigación educativa, para potenciar su publicación en las revistas científicas en este ámbito cada vez más pujante y relevante para las universidades. Sobre todo representan el deseo y el compromiso del profesorado de la ULL para la mejora del proceso educativo mediante la investigación, la evaluación y la reflexión compartida de nuestras prácticas y planteamientos docentes

Arquitectura, Salud y Confort: Solar Decathlon como caso de estudio para la propuesta de una nueva prueba de Salud y Confort

La arquitectura ha estado siempre relacionada con la medicina, ya que ambas tienen como objetivo final la salud y el confort de las personas. En base a las diferentes pruebas de SOLAR DECATHLON ganadas por la Universidad de Sevilla y artículos posteriores (art. HERRERA-MILLAN, incluido el estudio de implantación del modelo Aura en el Barrio de San Pablo, Sevilla), hemos llegado a la conclusión de que se estudia la Salud y el confort con parámetros medibles (humedad, temperatura, aire…). ¿Pero es todo lo que afecta al individuo en su salud y su confort? Por ello, este estudio tiene de objetivo crear una nueva prueba que complete y mejore la ya existente en cuanto a la Salud y el Confort. Para ello contaremos con un previo marco teórico o estado de la cuestión que nos situará en las diferentes variaciones que han tenido la Arquitectura y la Medicina hasta la actualidad. Dos disciplinas que han crecido entrelazadas a base de la resolución de problemas y corrección de errores. Conjunto a ello encontraremos también la forma de comparar tanto Salud con el Confort, como la intención de integrarlo en la arquitectura. Estudiando de manera simultánea la forma en la que la Arquitectura afecta sobre estos dos aspectos y como la prueba Solar Decathlon decide valorarlos. Tras esa base teórica, además de encuestas en las distintas participaciones del grupo Aura en S.D (LAC 2015 y EU 2019) y en la implantación en el barrio San Pablo, conseguiremos una base científica para a través de esta generar una metodología cualitativa, centrada en los aspectos que no se pueden cuantificar, y otra cuantitativa, centrada en los que si podemos cuantificar. Es decir, los aspectos medibles como la humedad, temperatura… y los no medibles tales como lo visual, olfativo, psíquico… Gracias a estas metodologías coexistentes necesarias, generaremos una nueva prueba que se amolde a las necesidades del ser humano, buscando su Salud y Confort en la vivienda.Universidad de Sevilla. Grado en Fundamentos de la Arquitectur